Bio-Rad Laboratories (BIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Accounts receivable | 2,553,100 | 2,684,200 | 2,699,400 | 2,886,489 | 2,531,135 |
| Accounts payable and accrued liabilities | -2,058,200 | -2,240,500 | -2,408,000 | -2,127,939 | -1,877,344 |
| Other Working Capital | 349,000 | 266,600 | 108,700 | 621,616 | 566,908 |
| Other Operating Activity | -388,700 | -335,400 | -205,700 | -710,702 | -635,727 |
| Operating Cash Flow | $455,200 | $374,900 | $194,400 | $669,464 | $584,972 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 28,700 | 174,200 | -994,200 | -538,171 | 119,601 |
| PPE Investments | -165,500 | -156,500 | -112,600 | -133,694 | -108,494 |
| Net Acquisitions | N/A | 2,500 | -99,300 | -125,516 | -84,415 |
| Purchase Sale Intangibles | N/A | N/A | -1,500 | N/A | 3,414 |
| Other Investing Activity | -23,400 | 0 | -1,500 | 0 | 3,414 |
| Investing Cash Flow | $-160,200 | $20,200 | $-1,207,600 | $-797,381 | $-69,894 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | 1,186,200 | -3,020 | N/A |
| Debt Repayment | -400 | -500 | -500 | N/A | -426,938 |
| Common Stock Issued | 19,200 | 18,500 | 17,600 | 20,632 | 20,198 |
| Common Stock Repurchased | -203,600 | -428,700 | -215,700 | -49,998 | -100,004 |
| Other Financing Activity | -34,000 | -14,900 | -14,000 | -23,043 | -16,297 |
| Financing Cash Flow | $-218,800 | $-425,600 | $973,600 | $-55,429 | $-523,041 |
| Exchange Rate Effect | 9,200 | 400 | 3,000 | -12,636 | 12,427 |
| Beginning Cash Position | 404,400 | 434,500 | 471,100 | 667,115 | 662,651 |
| End Cash Position | 489,800 | 404,400 | 434,500 | 471,133 | 667,115 |
| Net Cash Flow | $85,400 | $-30,100 | $-36,600 | $-195,982 | $4,464 |
| Free Cash Flow | |||||
| Operating Cash Flow | 455,200 | 374,900 | 194,400 | 669,464 | 584,972 |
| Capital Expenditure | -165,600 | -156,700 | -112,800 | -133,746 | -108,564 |
| Free Cash Flow | 289,600 | 218,200 | 81,600 | 535,718 | 476,408 |